Improving Weight Loss Outcomes for Binge Eating Disorder.

Sponsor
Drexel University (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03712462
Collaborator
Yale University (Other), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH)
126
1
2
53.4
2.4

Study Details

Study Description

Brief Summary

This study aims to develop and evaluate the efficacy of a behavioral weight loss treatment approach for individuals with binge eating disorder to both reduce their binge eating behaviors and lose weight.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Acceptance-Based Behavioral Weight Loss Therapy for BED
  • Behavioral: Standard Behavior Therapy
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
126 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The novel acceptance-based behavioral weight loss therapy is being compared to standard behavioral weight loss therapy for individuals with binge eating disorder.The novel acceptance-based behavioral weight loss therapy is being compared to standard behavioral weight loss therapy for individuals with binge eating disorder.
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Improving Weight Loss Outcomes for Binge Eating Disorder.
Actual Study Start Date :
Aug 20, 2018
Anticipated Primary Completion Date :
Jan 30, 2023
Anticipated Study Completion Date :
Jan 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: ABBT Weight Loss Therapy for BED

Acceptance-Based Behavioral Weight Loss Therapy for BED

Behavioral: Acceptance-Based Behavioral Weight Loss Therapy for BED
ABBT group therapy incorporates standard behavioral and acceptance-based strategies and was adapted to meet suit the unique needs of BED.

Active Comparator: Standard Behavior Therapy

Standard Behavioral Weight Loss Therapy

Behavioral: Standard Behavior Therapy
SBT group therapy will be adapted from the gold-standard standard behavioral therapy manuals used from previous weight loss studies.

Outcome Measures

Primary Outcome Measures

  1. Weight Loss [Changes from baseline assessment (before beginning treatment), to post-treatment assessment (1 year after baseline assessment), to follow-up assessment (2 years after baseline assessment)]

    Between-group changes in percent weight loss throughout the course of the study and at the one year follow-up assessment

Secondary Outcome Measures

  1. Eating Disorder Examination Questionnaire [Changes from each assessment time point throughout treatment (5 assessments over 1 year) and 1 year post-treatment follow-up assessment]

    The Eating Disorder Examination Questionnaire measures eating pathology. The EDE-Q yields four subscale scores: Restraint, Eating Concern, Shape Concern, and Weight Concern. The possible score range for each subscale is 0 to 6. The total score may also be reported (determined by averaging the subscale scores); the score range for the total score is also 0 to 6. For subscale scores and total score, higher scores indicate more severe pathology. The restraint sub-scale of the EDE-Q will be used to assess utilization of skills related to reducing dietary restraint. Assessing changes in EDE Global score and frequency of objective binge episodes.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Meet the DSM-5 criteria for Binge Eating Disorder

  • Have a BMI range of 27-50kg/m2

Exclusion Criteria:
  • are unable to fluently speak, write, and read English

  • are currently experiencing severe psychopathology that would limit their ability to engage in study (e.g., suicidality, substance use disorder, psychotic disorder)

  • are unable to engage in moderate physical activity (i.e., walk 2 blocks without rest)

  • have a medical condition (e.g., acute coronary syndrome, type I diabetes) that would pose a risk to the participant during intervention, cause a change in weight, or limit ability to comply with the recommendations of the program

  • Pregnant or planning to become pregnant in the next 2 years

  • Recently began a course of or changed the dosage of medication that can cause significant change in weight

  • Have a history of bariatric surgery

  • Have had weight loss of > 5% in the past 6 months

Contacts and Locations

Locations

Site City State Country Postal Code
1 Drexel University, Stratton Hall Philadelphia Pennsylvania United States 19104

Sponsors and Collaborators

  • Drexel University
  • Yale University
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Drexel University
ClinicalTrials.gov Identifier:
NCT03712462
Other Study ID Numbers:
  • 1803006178
First Posted:
Oct 19, 2018
Last Update Posted:
Sep 23, 2021
Last Verified:
Sep 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Drexel University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 23, 2021